| Literature DB >> 11901305 |
Ron H J Mathijssen1, Alex Sparreboom, Herlinde Dumez, Allan T van Oosterom, Ernst A de Bruijn.
Abstract
The systemic exposure to the anticancer agent irinotecan (CPT-11) and its active metabolite SN-38 were 79 and 92% reduced, respectively, relative to literature data, by concomitant phenytoin therapy. This finding suggests that increased doses of CPT-11 should be given to patients treated simultaneously with these drugs, to achieve adequate levels of SN-38.Entities:
Mesh：
Substances：
Year: 2002 PMID： 11901305 DOI： 10.1097/00001813-200202000-00004
Source DB: PubMed Journal: Anticancer Drugs ISSN： 0959-4973 Impact factor: 2.248